Overhead view of a doctor looking at his clipboard

Pipeline

Deep and Innovative Pipeline Addressing Immunological Disease

Product CandidatesDisease TargetsPreclinicalPhase 1Phase 2Phase 3

Reproxalap

Disease Targets: Dry Eye Disease

Type(ophthalmic solution)

Dry Eye Disease
Preclinical
Phase 1
Phase 2
Phase 3

Reproxalap

Disease Targets: Allergic Conjunctivitis

Type(ophthalmic solution)

Allergic Conjunctivitis
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Proliferative Vitreoretinopathy

Type(intravitreal injection)

Proliferative Vitreoretinopathy
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Primary Vitreoretinal Lymphoma

Type(intravitreal injection)

Primary Vitreoretinal Lymphoma
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Retinitis Pigmentosa

Type(intravitreal injection)

Retinitis Pigmentosa
Preclinical
Phase 1
Phase 2
Phase 3

RASP-Inhibitor Discovery Platform

Disease Targets: Multiple Immune-Mediated Retinal and Systemic Indications

Multiple Immune-Mediated Retinal and Systemic Indications
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Autoimmune Disease (Psoriasis)

Type(oral administration)

Autoimmune Disease (Psoriasis)
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Cytokine Release Syndrome (COVID-19)

Type(oral administration)

Cytokine Release Syndrome (COVID-19)
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Allergy (Atopic Asthma)

Type(oral administration)

Allergy (Atopic Asthma)
Preclinical
Phase 1
Phase 2
Phase 3